SCGB2B3P and esophageal cancer: Altogether these data suggest that PI3K-C2β may have a role in promoting resistance to chemotherapeutic drugs and that interference with PI3K-C2β activity might be a rational possibility for treatment of cisplatin-resistant esophageal cancer patients.